MedTech Strategist's complimentary Community Blog focuses on the people and the passions that drive the global medical device industry. Sign up for our e-Newsletter to receive new articles and video interviews directly to your inbox.
e-Newsletter Browse
To commercialize its multi-faceted tissue repair technology, TISSIUM is relying on a business model that will see it develop and commercialize some applications on its own and others in collaboration with larger, well-established partners. Excerpted from MedTech Strategist's recent feature on TISSIUM.
FDA’s first-ever ejection of a third-party reviewer. Excerpted from Pathways’ Picks, August 18, 2021
Digital health investment is now at an all-time high, according to Rock Health’s most recent report on H1 2021 funding trends. Excerpted from MedTech Strategist's recent feature, "Digital Health Deals Soar in First Half of 2021."
The National Medical Products Administration updated its policies and issued a draft guidance on designation and submissions of single-entity drug-device combination products. Importantly, NMPA made its submission requirements more flexible. Excerpted from Pathways’ Picks July 27.